These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7477981)

  • 1. Levodopa-induced dyskinesias are improved by fluoxetine.
    Durif F; Vidailhet M; Bonnet AM; Blin J; Agid Y
    Neurology; 1995 Oct; 45(10):1855-8. PubMed ID: 7477981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods of managing levodopa-induced dyskinesias.
    Giron LT; Koller WC
    Drug Saf; 1996 Jun; 14(6):365-74. PubMed ID: 8828014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
    Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia.
    Van Kampen JM; Stoessl AJ
    Neuroscience; 2000; 98(1):61-7. PubMed ID: 10858612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
    Zhang D; McGregor M; Bordia T; Perez XA; McIntosh JM; Decker MW; Quik M
    Mov Disord; 2015 Dec; 30(14):1901-1911. PubMed ID: 26573698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating and preventing levodopa-induced dyskinesias: current and future strategies.
    Durif F
    Drugs Aging; 1999 May; 14(5):337-45. PubMed ID: 10408734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
    Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
    Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
    Herring WJ; Assaid C; Budd K; Vargo R; Mazenko RS; Lines C; Ellenbogen A; Verhagen Metman L
    Clin Neuropharmacol; 2017; 40(6):255-260. PubMed ID: 29059133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
    Merims D; Ziv I; Sherki Y; Djaldetti R; Melamed E
    Neurol Neurochir Pol; 2001; 35 Suppl 3():65-8. PubMed ID: 12001656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients.
    Pierelli F; Adipietro A; Soldati G; Fattapposta F; Pozzessere G; Scoppetta C
    Acta Neurol Scand; 1998 May; 97(5):295-9. PubMed ID: 9613557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Henry B; Brotchie JM
    Drugs Aging; 1996 Sep; 9(3):149-58. PubMed ID: 8877309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A network centred on the inferior frontal cortex is critically involved in levodopa-induced dyskinesias.
    Cerasa A; Koch G; Donzuso G; Mangone G; Morelli M; Brusa L; Stampanoni Bassi M; Ponzo V; Picazio S; Passamonti L; Salsone M; Augimeri A; Caltagirone C; Quattrone A
    Brain; 2015 Feb; 138(Pt 2):414-27. PubMed ID: 25414038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Motor complications in dopa treatment of parkinson disease: clinical description and evaluation].
    Defebvre L
    Therapie; 2004; 59(1):93-6. PubMed ID: 15199675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Levodopa-induced dyskinesia in 176 patients with Parkinson's disease].
    Rocha MS; Andrade LA; Ferraz HB; Borges V
    Arq Neuropsiquiatr; 1995 Dec; 53(4):737-42. PubMed ID: 8729765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; Natté R; van den Munckhof P; Chase TN
    Neurology; 1998 Jul; 51(1):203-6. PubMed ID: 9674803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG; Scorticati MC; Micheli FE
    Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
    Stathis P; Konitsiotis S; Antonini A
    Expert Rev Neurother; 2015 Feb; 15(2):207-13. PubMed ID: 25578445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.